Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

dc.contributor.authorPapandreou, Christopherca
dc.contributor.authorBulló, Mònicaca
dc.contributor.authorTinahones Madueño, Francisco Joséca
dc.contributor.authorMartínez-González, Miguel Ángel, 1957-ca
dc.contributor.authorCorella, Doloresca
dc.contributor.authorFragkiadakis, Georgios A.ca
dc.contributor.authorLópez-Miranda, Joséca
dc.contributor.authorEstruch, Ramónca
dc.contributor.authorFitó Colomer, Montserratca
dc.contributor.authorSalas-Salvadó, Jordica
dc.date.accessioned2018-07-06T06:56:33Z
dc.date.available2018-07-06T06:56:33Z
dc.date.issued2017
dc.description.abstractBACKGROUND: Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. METHODS: A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15). RESULTS: At baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P < 0.05), were found; whereas a higher L-cystine to L-glutamate ratio (P < 0.05) was observed, in group 2 as compared to group 1.P-ether acylglycerophosphocholines, ceramides and sphingolipids were significantly different betweengroup 3 and group 1 (P < 0.05). Higher 16:1n-7 to 16:0, and 18:0 to16:0 ratio (P < 0.05), while lower 18:1n-9 to 18:0, 16:0 to 18:2n-6, and 18:3n-6 to 18:2n-6 ratio (P < 0.05) were observed in the final, compared to baseline values, in groups 2 and 3. CONCLUSION: The rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present.
dc.format.mimetypeapplication/pdf
dc.identifier.citationPapandreou C, Bullò M, Tinahones FJ, Martínez-González MÁ, Corella D, Fragkiadakis GA. Et al. Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. Nutr Metab (Lond). 2017 Sep 2;14:58. DOI: 10.1186/s12986-017-0213-3
dc.identifier.doihttp://dx.doi.org/10.1186/s12986-017-0213-3
dc.identifier.issn1743-7075
dc.identifier.urihttp://hdl.handle.net/10230/35041
dc.language.isoeng
dc.publisherBioMed Centralca
dc.relation.ispartofNutrition & Metabolism. 2017 Sep 2;14:58
dc.rightsCopyright © The Author(s). 2017. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.keywordFatty acid metabolism
dc.subject.keywordHepatic lipotoxicity
dc.subject.keywordMetabolomics
dc.subject.keywordNon-alcoholic fatty liver disease
dc.subject.otherFetge--Malalties
dc.subject.other
dc.titleSerum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trialca
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Papandreou-num-serv.pdf
Size:
373.85 KB
Format:
Adobe Portable Document Format

License

Rights